Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Genetic revelations in 2014 are testing traditional classification systems for movement disorders, and our approach to clinical diagnostics. Mutations in dystonia-associated genes lead to a spectrum of disorders with different phenotypes, underscoring the need for stringent clinical phenotyping of patients with movement disorders, as well as next-generation sequencing approaches.
Intravenous immunoglobulin (IVIg), is an effective anti-inflammatory and immunomodulatory treatment for many autoimmune diseases. In this Review, Lünemann and colleagues catalogue the evidence to support the use of IVIg in several neurological disorders, including Guillain–Barré syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. The authors also address diseases in which IVIg has not proven to be effective, and highlight avenues for future research, including drug development studies and clinical trials.
